Wide Ranks

BMRN

BioMarin Pharmaceutical Inc.

65.42

Top Statistics
Market Cap 12 B Forward PE 15.95 Revenue Growth 28.30 %
Current Ratio 4.27 Trailing PE 39.41 Earnings Growth 160.70 %
Profit Margins 11.71 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 28.49 Enterprise / Revenue 4.41 Price To Sales Trailing12 Months 4.53
Profitability
Profit Margins 11.71 % Operating Margins 15.27 %
Balance Sheet
Total Cash 930 M Total Cash Per Share 4.88 Total Debt 602 M
Total Debt To Equity 11.13 Current Ratio 4.27 Book Value Per Share 28.41
All Measures
Short Ratio 344.00 % Message Board Id finmb_25605 Shares Short Prior Month 5 M
Return On Equity 0.0625 City San Rafael Uuid bcd60339-c59b-3a43-af89-b10253407aca
Previous Close 64.88 First Trade Date Epoch Utc 932 M Book Value 28.41
Beta 0.3100 Total Debt 602 M Volume 950525
Price To Book 2.30 Fifty Two Week Low 61.15 Total Cash Per Share 4.88
Total Revenue 2 B Shares Short Previous Month Date 1 B Target Median Price 95.00
Max Age 86400 Recommendation Mean 1.67 Sand P52 Week Change 0.3133
Operating Margins 15.27 % Target Mean Price 98.02 Net Income To Common 322 M
Short Percent Of Float 0.0270 Implied Shares Outstanding 190 M Trailing Peg Ratio 40.94 %
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 930 M Next Fiscal Year End 1 B Revenue Per Share 14.53
Held Percent Insiders 0.0088 Ebitda Margins 15.48 % Trailing PE 39.41
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 64.88
Target Low Price 65.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 67.93
Open 65.16 Free Cashflow 144 M State CA
Dividend Yield 0.00 % Return On Assets 0.0300 Time Zone Short Name EST
Trailing Eps 1.66 Day Low 64.64 Address1 770 Lindaro Street
Shares Outstanding 190 M Price Hint 2 Target High Price 127.00
Website https://www.biomarin.com 52 Week Change -0.2817 Average Volume 1 M
Earnings Quarterly Growth 162.70 % Forward Eps 2.99 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 238.70 % Is_sp_500 False
Regular Market Day High 65.52 Profit Margins 11.71 % Debt To Equity 11.13
Fifty Two Week High 99.56 Day High 65.52 Shares Short 5 M
Regular Market Open 65.16 Industry Key biotechnology Earnings Growth 160.70 %
Enterprise To Revenue 4.41 Revenue Growth 28.30 % Shares Percent Shares Out 0.0268
Operating Cashflow 414 M Currency USD Time Zone Full Name America/New_York
Market Cap 12 B Is_nasdaq_100 False Zip 94901
Quote Type EQUITY Industry Biotechnology Long Name BioMarin Pharmaceutical Inc.
Regular Market Day Low 64.64 Held Percent Institutions 0.9756 Current Price 65.42
Enterprise To Ebitda 28.49 Financial Currency USD Current Ratio 4.27
Gross Margins 52.35 % Industry Disp Biotechnology Number Of Analyst Opinions 27
Country United States Float Shares 179 M Two Hundred Day Average 80.62
Ir Website http://investors.bmrn.com/index.cfm Enterprise Value 12 B Price To Sales Trailing12 Months 4.53
Forward PE 15.95 Regular Market Volume 950525 Ebitda 426 M
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.

The company serves specialty pharmacies, hospitals, and non-U.

S.

government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.

It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.

A.

; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation.

The company was incorporated in 1996 and is headquartered in San Rafael, California.